Hybrid Biotherapeutics Inc.
Irvine, United States (US) · Health and Medical
We built this page from public sources.
Do you work at Hybrid Biotherapeutics Inc.?
Claim this profile to manage your company.
Verified by Enterprise League
Data quality
Complete · Accuracy
Hybrid Biotherapeutics Inc. is a Health and Medical company based in Irvine, United States (US), with 2-10 employees. Hybrid Biotherapeutics Inc.'s profile is verified on Enterprise League.
Overview
Hybrid Biotherapeutics Inc is an Irvine, California-based biotechnology company pioneering a novel myeloid cell therapy platform for cancer treatment.
We are developing Hybrid Neutrophils, a first-in-class autologous cell therapy that dramatically enhances the effectiveness of therapeutic antibodies in solid tumors.
Our platform centers on naturally occurring Hybrid (APC-like) Neutrophils, discovered at the University of Pennsylvania, which combine potent cytotoxicity with professional antigen presentation, directly killing tumor cells and activating adaptive immunity.
Hybrid Biotherapeutics is led by a multidisciplinary team of experts in immunology, cell therapy, and oncology, with a proven track record of advancing complex biologics. We are currently focused on EGFR-positive colorectal cancer (CRC) and EGFR-mutated non-small cell lung cancer (NSCLC), with broad expansion potential across antibody-addressable solid tumors.
We are developing Hybrid Neutrophils, a first-in-class autologous cell therapy that dramatically enhances the effectiveness of therapeutic antibodies in solid tumors.
Our platform centers on naturally occurring Hybrid (APC-like) Neutrophils, discovered at the University of Pennsylvania, which combine potent cytotoxicity with professional antigen presentation, directly killing tumor cells and activating adaptive immunity.
Hybrid Biotherapeutics is led by a multidisciplinary team of experts in immunology, cell therapy, and oncology, with a proven track record of advancing complex biologics. We are currently focused on EGFR-positive colorectal cancer (CRC) and EGFR-mutated non-small cell lung cancer (NSCLC), with broad expansion potential across antibody-addressable solid tumors.
Contact Details
info@hybrid-bio.com
Irvine, United States (US), 5270 California Ave
Company Type
Private Limited Company
Employees
2-10
Categories
Companies teams usually look at after Hybrid Biotherapeutics Inc.
Comparing a few options usually leads to better decisions
Save companies to compare later. Useful when sharing options with your team
This is how your company profile looks to others.